Introduction
There is an increasing chorus of people recommending insulin as 'early' treatment of type 2 diabetes in both print [1 ] and at national meetings [2] . A subtext of this recommendation is to use insulin as the initial treatment for newly diagnosed patients with type 2 diabetes. The hope (in the absence of firm evidence) is that this approach will have a favorable effect on apoptosis of pancreatic b-cells and thus help preserve b-cell function. Initiating insulin treatment requires much time, effort and inconvenience on the part of both the patient and the provider. Before embarking on this course, a careful examination of the evidence supporting this recommendation is required. Moreover, if insulin is not selected as the initial treatment, consideration of when it should be used 'early' in the course of diabetes is also important. The clinical evidence for using insulin initially or 'early' is discussed, and based on this analysis, recommendations made.
Review of pertinent literature
Using insulin early in the course of type 2 diabetes is problematic because patients have varying periods of asymptomatic hyperglycemia, that is, undiagnosed diabetes, before the diagnosis is made. This has been shown to be 4-7 years and estimated to be as long as 9-12 years [3] . Furthermore, insulin secretion at diagnosis is already reduced by approximately 50% [4, 5] . Therefore, one can only speak of using insulin 'early' in relation to when the diagnosis is made. Currently, the standard clinical parameter of disease resolution is the glycemic response to therapy. Insulin secretion continues to deteriorate in spite of improving glycemia [4, 5] . Therefore, in this discussion, the timing of insulin therapy can only be related to the diagnosis, and the response can only be evaluated by glycemic changes and the need for subsequent therapies (Table 1) [6-9,10 ,11 ] . concentrations of less than 160 mg/dl and postprandial glucose concentrations of less than 200 mg/dl after 3-6 weeks of diet and exercise for 2 weeks of continuous subcutaneous insulin infusion (CSII). At hospitalization, their mean FPG and postprandial glucose concentrations were 218 and 304 mg/dl, respectively, and glycated hemoglobin levels by affinity chromatography were 11.0%. One patient could not be controlled satisfactorily on CSII and was an early failure. The mean FPG and postprandial glucose concentrations at discharge in the remaining 12 patients were 119 and 133 mg/dl, respectively, when CSII was discontinued. Satisfactory control was defined as FPG and postprandial glucose concentrations of less than 160 mg/dl and less than 200 mg/dl, respectively. At 6 months and 1 year, seven and six patients were still in satisfactory control, respectively. Changes in body weight did not predict success or failure.
Park and Choi [7] hospitalized 91 patients and treated them for 2-8 weeks with CSII. Prior to hospitalization, 47 had been treated with diet alone, 25 with oral hypoglycemic agents, 11 with neutral protamine Hagedorn (NPH) insulin alone and eight with a combination of NPH insulin and oral hypoglycemic agents. The mean duration of diabetes was 7.2 years and the mean HbA1c level when hospitalized was 13.2%. The criteria for remission was achieving and maintaining FPG and postprandial glucose concentrations of less than 108 mg/dl and less than 180 mg/dl, respectively, without medication. This occurred in 34% after the initial CSII therapy, 32% at 6 months and 31% at 1 year. Not unsurprisingly, the most important determinant of remission was the duration of diabetes. Remissions occurred in 62, 53, 22, 20 and 0% for durations of 1 or less, 2-5, 6-10, 11-15 and at least 16 years, respectively.
Ryan et al. [8] treated 16 newly diagnosed patients with FPG concentrations more than 200 mg/dl as outpatients for 2-3 weeks with a basal (NPH insulin)/bolus (regular insulin) regimen. They were in daily telephone contact with the study physician for dose adjustments. The mean FPG and HbA1c levels before insulin therapy were 239 mg/dl and 11.8%, respectively. The mean FPG concentration when insulin therapy was discontinued was 126 mg/dl. After 1 year, seven patients remained off medications, six were taking glyburide, two glyburide and metformin and one was receiving insulin again. The FPG and HbA1c levels for the entire group were 121 mg/dl and 6.6%, respectively. The only predictors for those who remained off medications were a smaller dose of insulin (0.32 vs. 0.73 units/kg) and a lower attained FPG concentration (106 vs. 139 mg/dl) at the end of insulin treatment.
Li et al. [9] hospitalized 138 newly diagnosed patients with FPG concentrations more than 200 mg/dl and treated them with CSII for 2 weeks. Their mean FPG, postprandial glucose and HbA1c levels before hospitalization were 245 mg/dl, 342 mg/dl and 10.1%, respectively. The goals of CSII therapy were FPG and postprandial glucose concentrations of less than 110 and less than 144 mg/dl, respectively. Twelve patients failed to achieve these targets. At discharge, FPG and postprandial glucose concentrations in the 126 successfully treated patients were 113 and 155 mg/dl, respectively. All medications were stopped and the patients followed on diet and exercise alone. Relapse was defined as either a FPG or postprandial glucose concentration of more than 126 and more than 180 mg/dl, respectively, which had to be confirmed on a separate day. At 6 months, 91 patients were still being followed, 67% of whom remained off medication. At 1 year, 68 patients were still being followed, 47% of whom remained off medication. Only a slightly, but significantly (P ¼ 0.035), lower FPG concentration after CSII predicted remission at 1 year [110 AE 22 (SD) vs. 121 AE 20 mg/dl]. There was no difference in the insulin doses.
Chen et al.
[12 ] hospitalized 50 consecutive newly diagnosed patients with type 2 diabetes whose FPG glucose concentrations were more than 300 mg/dl or random glucose concentrations were more than 400 mg/dl and treated them intensively with insulin for 10-14 days. At discharge, 30 of the 50 individuals were randomly assigned to continue insulin treatment (more than half because of the concern that some patients would refuse longer term insulin therapy) and 20 randomly assigned to treatment with oral antidiabetic drugs (OADs), metformin in obese patients and gliclazide-modified release (MR) in lean ones. At 6 months, the insulin-treated group was also switched to OAD. Upon initial hospitalization, glycemic status was similar in the patients subsequently maintained on insulin for 6 months and in those switched to oral medications at discharge as follows: peak FPG concentrations, 345 vs. 329 mg/dl, respectively; peak random glucose concentrations, 527 vs. 483 mg/dl, respectively; and HbA1c levels, 11.9 vs. 11.3%, respectively. FPG and HbA1c levels were significantly lower in the patients treated with insulin during the first 6 months after discharge and remained so during the subsequent 6 months after they were switched to OAD. However, during the first 6 months, the mean dose of glicazide-MR was only 54.5 mg/day, less than half of the maximal dose of 120 mg/day. No information was given concerning the doses during the subsequent 6 months for either group.
Two studies compared initial treatment with insulin to a sulfonylurea with or without metformin on subsequent maintenance of near euglycemia without medications.
Weng et al. [10 ] , in a multicenter study, randomized newly diagnosed patients to be initially treated with CSII, of whom 124 completed the study, or multiple daily injections (MDIs) of insulin, of whom 113 completed the study, or oral medications (gliclazide and/or metformin), of whom 94 completed the study. Doses were adjusted daily in the insulin groups and every 3 days in the sulfonylurea/metformin group. Glycemic status at randomization was comparable in the CSII, MDI and oral medication groups as follows: HbA1c levels (%), 9.8, 9.7 and 9.5, respectively; FPG concentrations (mg/dl), 203, 207 and 194, respectively; and 2-h postprandial glucose concentrations (mg/dl), 290, 315 and 299, respectively. Successful initial therapy was defined as FPG or 2-h postprandial glucose concentrations of less than 110 mg/dl and less than 144 mg/dl, respectively, which needed to be achieved within 2 weeks. After the initial therapy, glycemic control was again comparable among the three groups as follows: FPG concentrations (mg/dl), 119, 122 and 117, respectively; 2-h glucose concentrations (mg/dl), 135, 146 and 148, respectively. Therapy was continued for two more weeks at which time all treatment was stopped and the patients kept on diet and exercise alone. Relapse was defined as a FPG or a 2-h postprandial glucose concentration of more than 126 mg/dl and more than 180 mg/dl, respectively, which had to be confirmed 1 week later. Remissions in the three groups at 6 months (estimated from a graph) were 56, 48 and 32%, respectively. At 1 year, the remissions (stated in the text) were 51, 45 and 27%, respectively. Those who relapsed were shifted to standard therapy. However, HbA1c levels at 1 year were no different among patients originally randomized to the three groups as follows: 6.4, 6.6 and 6.7%, respectively [13 ] .
Chandra et al.
[11 ] explained treatment options and the possibility of long-term benefits of insulin therapy to newly diagnosed type 2 diabetic patients with fasting blood glucose (FBG) concentrations more than 200 mg/dl and allowed them to choose between an sulfonylurea or insulin, enrolling 30 in each group. Patients selecting the sulfonylurea were started on 60 mg of gliclazide-MR once a day and advised to perform self-monitoring of blood glucose (SMBG) before breakfast and at bedtime. The dose was reduced to 30 mg if the FBG was less than 90 mg/dl for two consecutive days and stopped if on that dose the FBG remained less than 90 mg/dl for at least 1 week. FBG's were then measured every third day and gliclazide restarted if values were more than 110 mg/dl on more than two occasions. The insulin regimen was premixed 70/30 insulin given twice a day, starting with 10 units before breakfast and 6 units before supper.
Patients were instructed to perform SMBG before each injection and decrease the dose by two units if the preprandial value was less than 100 mg/dl on two consecutive days (in consultation with a study physician who was available around-the-clock by telephone). When the daily dose reached four units and euglycemia, defined as a FBG less than 110 mg/dl, was maintained for over a week, or the patient experienced hypoglycemia, the insulin was discontinued. It was restarted if the FBG concentration increased to more than 110 mg/dl. Remission was defined as 'euglycemia' off drug treatment for a minimum of 1 month. Initial glycemia was comparable in the insulin and sulfonylurea groups with HbA1c levels of 10.4% and FBG concentrations of $250 mg/dl in each. FBG concentrations normalized within 2-6 weeks in both groups and remained similar throughout the study with data available up to 2 years. Consistent with the FBG data, HbA1c levels were similar at 6 months, 6.8% in patients originally assigned to insulin and 6.2% in the sulfonylurea group. However, at 6 months, only one of 30 patients (3%) taking gliclazide was in remission, whereas 24 out of 30 (80%) originally assigned to insulin were. At 1 year, one out of 20 (5%) in the sulfonylurea group remained in remission while 10 out of 16 (62%) in the insulin group did.
In the United Kingdom Prospective Diabetes Study Group (UKPDS), patients with newly diagnosed diabetes were treated initially with diet alone for 3 months [14] . Those who still had hyperglycemic symptoms or whose FPG concentrations were more than 270 mg/dl after this initial treatment were randomized to receive either insulin (N ¼ 178) or a sulfonylurea (N ¼ 231). Ultralente insulin was started but if preprandial or bedtime glucose concentrations were more than 126 mg/dl, short-acting insulin was added two or three times a day, or twice daily injections of intermediate-acting and short-acting insulin were used. The initial FPG concentrations (284 mg/dl) were identical in the two groups, whereas the HbA1c levels were almost so (10.6 vs. 10.5%). There was little difference in the HbA1c levels between the insulin and sulfonylurea groups at 1 year (7.0 vs. 6.8%).
Alvarsson et al. [15] followed 39 randomized type 2 diabetic patients within 2 years of diagnosis who were being treated with diet alone for at least 1 month and had not received more than 6 months of pharmacological therapy before entry and followed them for 2 years. Initial HbA1c levels in those allocated to insulin (N ¼ 18) and glibenclamide (glyburide) (N ¼ 21) were 7.3 and 6.9%, respectively. They remained slightly, but significantly, lower 1 and 2 years later in the insulin group with the mean values in both groups less than 7.0%. However, the average dose of the sulfonylurea was only 3.0 mg/day, far below the maximal amount. Furthermore, the guideline for the need to switch to insulin in this study was an HbA1c level more than 3% above the upper reference limit.
Discussion
In general, approximately half of newly diagnosed type 2 diabetic patients who were initially treated intensively with insulin were able to achieve near euglycemia without medications for at least a year after the insulin was discontinued (Table 1) . Should these results now turn us to initiating treatment with insulin in newly diagnosed type 2 diabetic patients? I think not for several reasons. First, patients started on insulin were either hospitalized [6, 7, 9, 12 ] or contacted their physicians daily [8, 10 ] or every several days [11 ] . This is simply not feasible in current western medical care systems. Second, newly diagnosed type 2 diabetic patients treated with OAD achieved and maintained goal HbA1c levels [10 ,11 ,14,15] . Third, although insulin will certainly bring a patient under control, compare what is required from physicians and patients when insulin or OAD are started (Table 2 ). Quite a difference for both parties. Although analogue insulins were not used in most of the studies discussed, these do not change the requirements of initiating insulin therapy. Finally, patients have diabetes for many years, usually for the remainder of their lives. How clinically important might a short period of no medications after initial intensive insulin therapy be given the length of time patients will have to have pharmacological treatment?
Note that I have restricted these comments to glycemic outcomes, not physiological ones. The rationale for initial therapy with insulin is the belief that this treatment will reverse the increased apoptosis of pancreatic b-cells seen in type 2 diabetic patients [16] and thus allow improved metabolic control over a longer period without more intensification of therapy. Peter Butler discussed this issue during the Scientific Sessions of the 2008 American Diabetes Association (ADA) national meeting in which he confirmed that the frequency of b-cell apoptosis is increased in people with type 2 diabetes. However, a subanalysis of the cases with type 2 diabetes when divided into those on insulin vs. those on OAD did not show that the insulin-treated patients had lower b-cell apoptosis. On the contrary, these small numbers of observations do not resolve this issue because those receiving 110 Diabetes and the endocrine pancreas I insulin probably had a longer duration of diabetes and more b-cell dysfunction.
Although a number of the studies utilizing initial intensive insulin therapy described above have also shown some temporary preservation of insulin secretion, this is of unproven clinical benefit. This is in marked contrast to the virtual absence of the development or progression of diabetic retinopathy and nephropathy in over 2000 patients whose average HbA1c levels were maintained less than 7.0% over 4-9 years [17] [18] [19] [20] [21] . Finally, even though the ADA recommends insulin therapy in severely hyperglycemic, symptomatic type 2 diabetic patients [22 ] , it really is not necessary under these circumstances. High doses of sulfonylurea will quickly bring these patients under control [11 ,14,23] as rapidly as insulin [11 ,14] . Severely hyperglycemic, newly diagnosed type 2 diabetic patients are often hospitalized and started on insulin at my county institution and invariably have near euglycemia (and often hypoglycemia) when first seen in our diabetes clinic. We then have to discontinue the insulin and place them on metformin as recommended by the ADA [22 ] .
One must keep in mind that the risk benefit profiles of different OADs are not equal, and furthermore, that these profiles compared with insulin over time remain incompletely understood. However, at this time, there is no evidence that the early use of insulin provides sufficient physiologic advantage to warrant the money, time and resources of patients and providers that are necessary to implement this treatment in a successful, timely manner. Although most studies of the early use of insulin did not use glargine or other longer acting analogues, use of these insulins would not address the issues raised in Table 2 .
Conclusion
In my view, OADs should be the initial treatment for type 2 diabetes and continued as long as HbA1c levels are kept below 7.0%. This is much easier for both physicians and their patients and control is not compromised. When a combination of two [24] or three [25] [26] [27] [28] 29 ] OADs that had been successful finally fail, that is the time for the 'early' use of insulin. Too often, insulin treatment at this point is not happening. For instance, the HbA1c level of nearly 1000 patients on combination OADs in a large HMO was 9.2% when insulin was started [30] . While on combination OADs, these patients spent 30 months with HbA1c levels more than 8.0% and 58 months with HbA1c levels more than 7.0% prior to insulin therapy. Therefore, our biggest challenge is to overcome the 'insulin resistance' of patients, and frankly and probably more important, of physicians. Unfortunately, clinical inertia is alive and well and, in my opinion, is the main reason why so many type 2 diabetic patients remain uncontrolled.
Treating to target is the crucial goal. It does not seem to matter how we arrive there (absent troubling side effects of the therapeutic approach). Why make it harder on our patients and ourselves as long as we get (and stay) there? Let us just do it as simply as possible.
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